Show simple item record

dc.contributor.authorFox, Kathleen M
dc.contributor.authorWang, L
dc.contributor.authorGandra, S. R
dc.contributor.authorQuek, R. G. W
dc.contributor.authorLi, L
dc.contributor.authorBaşer, Onur
dc.date.accessioned2019-02-28T13:04:26Z
dc.date.accessioned2019-02-28T11:08:14Z
dc.date.available2019-02-28T13:04:26Z
dc.date.available2019-02-28T11:08:14Z
dc.date.issued2015
dc.identifier.citationFox, K. M., Wang, L., Gandra, S. R., Quek, R. G., Li, L., & Baser, O. (January 01, 2015). Long-Term Economic Burden Associated With Cardiovascular Events Among High-Risk Patients With Hyperlipidemia. Value in Health, 18, 3.p. 139-140.en_US
dc.identifier.issn1098-3015
dc.identifier.issn1524-4733
dc.identifier.otherWOS:000354498502152
dc.identifier.urihttp://dx.doi.org/10.1016/j.jval.2015.03.811
dc.identifier.urihttps://hdl.handle.net/20.500.11779/626
dc.descriptionOnur Başer (MEF Author)en_US
dc.description.abstractObjectives: This study evaluated the economic burden associated with new cardiovascular events (CVEs) for 3 years post-CVE among high-risk patients diagnosedwith hyperlipidemia. Methods: A retrospective cohort study was conductedamong high-risk hyperlipidemic patients with and without a new CVE, using IMSLifeLink PharMetrics Plus data 01/01/2006-06/30/2012. CVEs included primary inpatient claims for myocardial infarction, unstable angina, ischemic stroke, transientischemic attack, revascularization and heart failure. Patients were assigned torisk cohorts based on history of CVE and coronary heart disease risk equivalent(CHD RE) condition. Propensity score matching was applied to compare healthcarecosts among patients with and without new CVEs, ranging from 1 month (acutephase) to 3 years post-CVE date. Results: A total of 21,482 matched patientswere included in the history of CVE cohort and 181,228 in the CHD RE cohort.Hyperlipidemic patients with new CVEs were, on average, aged 65-72 years, bothcohorts had 65.2% male and 74.7-84.4% had hypertension (most common baselinecomorbidity). Total costs per patient per month (PPPM) were significantly higheramong patients with versus without new CVEs during the acute phase (history ofCVE: $27,247 vs. $1,586; CHD RE: $30,742 vs. $914; p<0.0001) and remained higherduring years 1, 2 and 3, respectively, post-CVE among patients in the history of CVEcohort ($2,603 vs. $1,252; $2,055 vs. $1,191; $2,061 vs. $1,166, p<0.0001) and CHD REcohort ($1,926 vs. $844; $1,535 vs. $850; $1,475 vs. $853, p<0.0001). Significant costdifferences were observed between patients with and without new CVEs in bothcohorts, including inpatient, outpatient, emergency room and pharmacy visit costsPPPM, during 1-3 years post-CVE. Conclusions: Healthcare costs for high-riskpatients with new CVEs remained significantly higher than for matched patients without CVEs for up to 3 years post-CVE, imposing a significant economic burdenon U.S. commercial payers.en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.jval.2015.03.811en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePCV58 - Long-term economic burden associated with cardiovascular events among high-risk patients with hyperlipidemiaen_US
dc.typeconferenceObjecten_US
dc.relation.journalValue in Healthen_US
dc.contributor.departmentİİSBF, Ekonomi Bölümüen_US
dc.identifier.volume18en_US
dc.identifier.issue3en_US
dc.identifier.startpage139en_US
dc.identifier.endpage140en_US
dc.relation.publicationcategoryUluslararası Konferans Öğesien_US


Files in this item

This item appears in the following Collection(s)

Show simple item record